{"id":"NCT02627963","sponsor":"AVEO Pharmaceuticals, Inc.","briefTitle":"A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)","officialTitle":"A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-24","primaryCompletion":"2018-10-04","completion":"2021-06-21","firstPosted":"2015-12-11","resultsPosted":"2020-02-20","lastUpdate":"2023-07-18"},"enrollment":350,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Renal Cell"],"interventions":[{"type":"DRUG","name":"Tivozanib hydrochloride","otherNames":[]},{"type":"DRUG","name":"Sorafenib","otherNames":[]}],"arms":[{"label":"Tivozanib hydrochloride","type":"EXPERIMENTAL"},{"label":"Sorafenib","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase 3, open-label, randomized, controlled, multi-national, multi-center, parallel-arm study comparing tivozanib to sorafenib in participants with refractory advanced renal cell carcinoma (RCC).\n\nParticipants will be randomized (1:1) to treatment with tivozanib or sorafenib.\n\nParticipants will be stratified by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk category (favorable; intermediate; poor) and prior therapy (two prior vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKI); a prior checkpoint inhibitor \\[programmed cell death -1 protein (PD-1) or PD-1 ligand (PD1-L) inhibitor\\] plus a prior VEGFR TKI; a prior VEGFR TKI plus any other systemic agent).\n\nAll participants will be evaluated for progression free survival, overall survival, objective response rate, and the duration of response as well as safety and tolerability.\n\nPharmacokinetic (PK) analyses are also included in study.","primaryOutcome":{"measure":"Progression-free Survival (PFS)","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first. Disease progression was assessed every 8 weeks (up to approximately 5 years)","effectByArm":[{"arm":"Tivozanib Hydrochloride","deltaMin":5.59,"sd":null},{"arm":"Sorafenib","deltaMin":3.88,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0165"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":191,"countries":["United States","Belgium","Canada","Czechia","Denmark","France","Germany","Hungary","Italy","Poland","Spain","United Kingdom"]},"refs":{"pmids":["36576430","33980467","31810797"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":81,"n":173},"commonTop":["Diarrhoea","Hypertension","Decreased appetite","Fatigue","Palmar-plantar erythrodysaesthesia syndrome"]}}